Sign In
Buy KROS
$11.15
+0.500 (+4.69%)
At Close: Aug 07, 2026
KROS or NVZMY: Which Is the Better Value Stock Right Now?
12:41pm, Wednesday, 26'th Nov 2025
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Keros Therapeutics, Inc. (KROS) and Novozymes A/S (NVZMY). But which of these two stocks offers valu
How Much Upside is Left in Keros Therapeutics (KROS)? Wall Street Analysts Think 34.24%
10:56am, Wednesday, 26'th Nov 2025
The consensus price target hints at a 34.2% upside potential for Keros Therapeutics (KROS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earning
Keros Therapeutics Announces Final Results of Tender Offer
04:01pm, Thursday, 20'th Nov 2025
LEXINGTON, Mass., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), today announced the final results of its cash tender offer (the “Tende
Keros Therapeutics Announces Preliminary Results of Tender Offer
06:00am, Wednesday, 19'th Nov 2025
LEXINGTON, Mass., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), today announced the preliminary results of its cash tender offer (the �
5 Undervalued Stocks That Are Poised for Growth in November
08:36am, Thursday, 13'th Nov 2025
Five undervalued picks - including StoneCo and MillerKnoll - shine with strong growth prospects and low price-to-book ratios this November.
KROS vs. ARGX: Which Stock Is the Better Value Option?
12:49pm, Monday, 10'th Nov 2025
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Keros Therapeutics, Inc. (KROS) or argenex SE (ARGX). But which of these two stocks is more a
Wall Street Analysts See a 42.78% Upside in Keros Therapeutics (KROS): Can the Stock Really Move This High?
10:56am, Monday, 10'th Nov 2025
The consensus price target hints at a 42.8% upside potential for Keros Therapeutics (KROS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earning
Keros Therapeutics, Inc. (KROS) Reports Q3 Loss, Tops Revenue Estimates
06:41pm, Wednesday, 05'th Nov 2025
Keros Therapeutics, Inc. (KROS) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $1.11. This compares to a loss of $1.41 per share a year ago.
Keros Therapeutics Reports Third Quarter 2025 Financial Results
04:01pm, Wednesday, 05'th Nov 2025
LEXINGTON, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and com
Y Intercept Hong Kong Ltd Invests $1.40 Million in Keros Therapeutics, Inc. $KROS
03:41am, Monday, 03'rd Nov 2025
Y Intercept Hong Kong Ltd bought a new position in Keros Therapeutics, Inc. (NASDAQ: KROS) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Ex
Keros Therapeutics (KROS) Moves 9.8% Higher: Will This Strength Last?
10:46am, Tuesday, 21'st Oct 2025
Keros Therapeutics (KROS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price i
Keros Therapeutics Commences Issuer Tender Offer to Repurchase up to $194.4 Million Shares
06:00am, Monday, 20'th Oct 2025
LEXINGTON, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and com
Keros Therapeutics Announces Plan for Return of $375 Million in Excess Capital
06:30am, Wednesday, 15'th Oct 2025
Agrees to Repurchase of All Shares Held By ADAR1 Capital Management and Pontifax Venture Capital Plans to Commence Tender Offer to Repurchase up to $194 Million of Additional Shares LEXINGTON, Mass.,
LEXINGTON, Mass., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel t
Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences
04:01pm, Thursday, 28'th Aug 2025
LEXINGTON, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and com
